• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ofatumumab and its role as immunotherapy in chronic lymphocytic leukemia.

作者信息

Sandhu Suneet, Mulligan Stephen P

机构信息

Department of Haematology, Royal North Shore Hospital, St Leonards, NSW Kolling Institute, University of Sydney, St Leonards, NSW, Australia.

Department of Haematology, Royal North Shore Hospital, St Leonards, NSW Kolling Institute, University of Sydney, St Leonards, NSW, Australia

出版信息

Haematologica. 2015 Apr;100(4):411-4. doi: 10.3324/haematol.2015.124107.

DOI:10.3324/haematol.2015.124107
PMID:25828085
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4380711/
Abstract
摘要

相似文献

1
Ofatumumab and its role as immunotherapy in chronic lymphocytic leukemia.奥法木单抗及其在慢性淋巴细胞白血病中作为免疫疗法的作用。
Haematologica. 2015 Apr;100(4):411-4. doi: 10.3324/haematol.2015.124107.
2
Monoclonal antibodies in chronic lymphocytic leukemia.慢性淋巴细胞白血病中的单克隆抗体
Expert Rev Anticancer Ther. 2006 Sep;6(9):1231-8. doi: 10.1586/14737140.6.9.1231.
3
[Advances in the treatment of chronic lymphocytic leukaemia].[慢性淋巴细胞白血病的治疗进展]
Med Clin (Barc). 2016 Nov 18;147(10):447-454. doi: 10.1016/j.medcli.2016.05.034. Epub 2016 Jul 16.
4
Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study.奥法木单抗单药治疗氟达拉滨难治性慢性淋巴细胞白血病：一项关键研究的最终结果
Haematologica. 2015 Aug;100(8):e311-4. doi: 10.3324/haematol.2014.121459. Epub 2015 Mar 13.
5
Ofatumumab for treating chronic lymphocytic leukemia: a safety profile.奥法木单抗治疗慢性淋巴细胞白血病：安全性概况。
Expert Opin Drug Saf. 2015;14(12):1945-59. doi: 10.1517/14740338.2015.1113253. Epub 2015 Nov 13.
6
Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.奥法妥木单抗治疗新诊断和复发/难治性慢性淋巴细胞白血病。
Expert Rev Anticancer Ther. 2011 Feb;11(2):151-60. doi: 10.1586/era.10.223.
7
Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia.慢性淋巴细胞白血病中单独及联合靶向药物的抗体疗法
Semin Oncol. 2016 Apr;43(2):280-90. doi: 10.1053/j.seminoncol.2016.02.010. Epub 2016 Feb 8.
8
Oral high-dose glucocorticoids and ofatumumab in fludarabine-resistant chronic lymphocytic leukemia.口服大剂量糖皮质激素与奥法木单抗治疗氟达拉滨耐药的慢性淋巴细胞白血病
Leukemia. 2012 May;26(5):1144-5. doi: 10.1038/leu.2011.329. Epub 2011 Nov 8.
9
Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy.奥法妥木单抗在裂解全血中的 B 慢性淋巴细胞白血病细胞方面比利妥昔单抗更有效，并且与化疗联合使用时也是如此。
J Immunol. 2013 Jan 1;190(1):231-9. doi: 10.4049/jimmunol.1202645. Epub 2012 Dec 5.
10
Targeted Agents for the Frontline Management of Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病一线治疗的靶向药物
Clin Adv Hematol Oncol. 2016 May;14(5 Suppl 8):7-12.

引用本文的文献

1
Beyond BCL2 (B cell lymphoma) and BTK (Bruton tyrosine kinase) inhibitors: novel agents and resistance mechanisms for chronic lymphocytic leukemia.超越BCL2（B细胞淋巴瘤）和BTK（布鲁顿酪氨酸激酶）抑制剂：慢性淋巴细胞白血病的新型药物及耐药机制
Discov Oncol. 2025 Jun 14;16(1):1100. doi: 10.1007/s12672-025-02947-9.
2
Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells.癌症免疫疗法靶向 CD20 的进展：从开创性的单克隆抗体到嵌合抗原受体修饰的 T 细胞。
Front Immunol. 2024 Apr 4;15:1363102. doi: 10.3389/fimmu.2024.1363102. eCollection 2024.
3
Potential role of immunotherapy and targeted therapy in the treatment of cancer: A contemporary nursing practice.免疫疗法和靶向疗法在癌症治疗中的潜在作用：当代护理实践
Heliyon. 2024 Jan 17;10(2):e24559. doi: 10.1016/j.heliyon.2024.e24559. eCollection 2024 Jan 30.
4
Advances in natural products and antibody drugs for SLE: new therapeutic ideas.系统性红斑狼疮天然产物和抗体药物的进展：新的治疗思路
Front Pharmacol. 2023 Jul 10;14:1235440. doi: 10.3389/fphar.2023.1235440. eCollection 2023.
5
T Cell Defects and Immunotherapy in Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病中的T细胞缺陷与免疫治疗
Cancers (Basel). 2021 Jun 29;13(13):3255. doi: 10.3390/cancers13133255.
6
Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies.新型嵌合 IgA CD20 抗体：增强针对 CD20 阳性恶性肿瘤的中性粒细胞活化。
MAbs. 2020 Jan-Dec;12(1):1795505. doi: 10.1080/19420862.2020.1795505.
7
miR-218 inhibits acute promyelocytic leukemia cell growth by targeting BMI-1.微小RNA-218通过靶向BMI-1抑制急性早幼粒细胞白血病细胞的生长。
Oncol Lett. 2017 Dec;14(6):8078-8083. doi: 10.3892/ol.2017.7220. Epub 2017 Oct 19.
8
Ofatumumab - a valid treatment option for chronic lymphocytic leukemia patients.奥法妥木单抗——慢性淋巴细胞白血病患者的有效治疗选择。
Ther Clin Risk Manag. 2017 Jul 20;13:905-907. doi: 10.2147/TCRM.S140023. eCollection 2017.
9
Immunotherapy in Chronic Lymphocytic Leukaemia (CLL).慢性淋巴细胞白血病（CLL）的免疫疗法
Curr Hematol Malig Rep. 2016 Feb;11(1):29-36. doi: 10.1007/s11899-015-0295-9.

本文引用的文献

1
Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study.奥法妥木单抗联合地塞米松治疗复发或难治性慢性淋巴细胞白血病患者：一项 II 期研究结果。
Am J Hematol. 2015 May;90(5):417-21. doi: 10.1002/ajh.23964. Epub 2015 Apr 1.
2
Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study.奥妥珠单抗作为慢性淋巴细胞白血病的一线治疗：CLL11研究的更新结果。
Leukemia. 2015 Jul;29(7):1602-4. doi: 10.1038/leu.2015.14. Epub 2015 Jan 30.
3
Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia.奥法木单抗治疗预后不良的慢性淋巴细胞白血病：一项来自欧洲慢性淋巴细胞白血病研究倡议的IV期非干预性观察性研究。
Haematologica. 2015 Apr;100(4):511-6. doi: 10.3324/haematol.2014.118158. Epub 2015 Jan 16.
4
Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.序贯使用奥法妥木单抗和来那度胺治疗复发难治性慢性淋巴细胞白血病和小淋巴细胞淋巴瘤。
Leuk Lymphoma. 2015 Mar;56(3):645-9. doi: 10.3109/10428194.2014.935369.
5
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.伊布替尼与奥法妥木单抗治疗既往治疗的慢性淋巴细胞白血病。
N Engl J Med. 2014 Jul 17;371(3):213-23. doi: 10.1056/NEJMoa1400376. Epub 2014 May 31.
6
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.奥滨尤妥珠单抗联合苯丁酸氮芥治疗伴有合并症的 CLL 患者。
N Engl J Med. 2014 Mar 20;370(12):1101-10. doi: 10.1056/NEJMoa1313984. Epub 2014 Jan 8.
7
Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial.苯达莫司汀联合奥法妥木单抗治疗复发/难治性慢性淋巴细胞白血病：一项 GIMEMA 多中心 II 期试验。
Leukemia. 2014 Mar;28(3):642-8. doi: 10.1038/leu.2013.334. Epub 2013 Nov 13.
8
Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.奥法木单抗联合化疗治疗未经治疗的慢性淋巴细胞白血病患者。
Blood. 2011 Jun 16;117(24):6450-8. doi: 10.1182/blood-2010-12-323980. Epub 2011 Apr 15.
9
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.利妥昔单抗联合氟达拉滨和环磷酰胺治疗慢性淋巴细胞白血病患者的随机、开放标签、3 期临床试验。
Lancet. 2010 Oct 2;376(9747):1164-74. doi: 10.1016/S0140-6736(10)61381-5.
10
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.奥法妥木单抗作为单一药物 CD20 免疫疗法在氟达拉滨难治性慢性淋巴细胞白血病中的应用。
J Clin Oncol. 2010 Apr 1;28(10):1749-55. doi: 10.1200/JCO.2009.25.3187. Epub 2010 Mar 1.